We like to thank our colleagues Freudenmann et al. for their constructive and differentiated criticism. However, we like to point out that in the summaries of product characteristics (SmPCs), especially of those antipsychotics named by you, hypertension, apart from orthostatic dysregulation and hypotension, is listed as very common adverse event (quetiapine), common adverse event (clozapine) or after the use of an injectable formulation (risperidone). This also applies to amitriptyline as a tricyclic antidepressant. Our article’s perspective is that of a physician investigating possible causes of treatment-resistant hypertension. Here, the patient’s medication history should also take rare adverse reactions to psychiatric medications into consideration.
The new antidepressants highlighted by you represent an important addition to the substances we listed in our table in a very summarizing fashion due to lack of space.
Prof. Dr. med. Franz Weber
St. Walburga-Krankenhaus, Meschede
Prof. Dr. med. Manfred Anlauf
Privatpraxis im Medizinischen Versorgungszentrum, Dialyse-Zentrum, Cuxhaven
Conflict of interest statement
The authors declare that no conflict of interest exists.
|1.||Weber F, Anlauf M: Treatment resistant hypertension—investigation and conservative management. Dtsch Arztebl Int 2014; 111: 425–31. VOLLTEXT|